24 February 2022 
EMA/CHMP/107190/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Pifeltro 
doravirine 
On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Pifeltro. The marketing authorisation holder for this medicinal product is Merck Sharp & Dohme B.V. 
The CHMP adopted an extension to the existing indication as follows:2  
Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the 
treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg 
infected with HIV-1 without past or present evidence of resistance to the NNRTI class (see 
sections 4.4 and 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
